A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Inclusion Criteria: * Adult patients, \>/= 45 years of age * Established cardiovascular disease A stable coronary disease B cerebrovascular disease C peripheral artery disease * Without established coronary disease D pharmacologically treated type 2 diabetes mellitus and one or more risk factor(s) for cardiovascular disease E 3 or more risk factors for cardiovascular disease * Receiving evidence-based medical and dietary management of dyslipidemia Exclusion Criteria: * Occurrence of myocardial infarction, hospitalization for unstable angina, stroke or revascularization (coronary, carotid or peripheral) within three months prior to randomization * Uncontrolled hypertension * Uncontrolled diabetes * Concomitant treatment with any other drug raising HDL-C * Previous treatment with compounds targeting cholesteryl ester transfer protein (CETP)